Targeting EZH2 in combination with translational and kinase signaling inhibitors may thus offer a powerful strategy to overcome lineage plasticity, restore treatment sensitivity, and suppress progression in aggressive PCa. This evidence concerns the gene EZH2 and posterior cortical atrophy.